Ondansetron
Side effects
Options:
Hide MedDRA Preferred Terms
,
display all 38 labels
MedDRA Preferred Term
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
Wound
|
Wound
|
10.6% - 27.6%
|
11.8% - 30.5%
|
|
|
x
|
x
|
|
|
x
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Somnolence
|
Drowsiness
|
5.43% - 20.4%
|
6.76% - 23%
|
|
|
x
|
x
|
|
|
x
|
x
|
|
x
|
x
|
x
|
|
|
|
x
|
|
x
|
|
x
|
Headache
|
Headache
|
very common, 5.83% - 27.2%
|
5.08% - 15%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Musculoskeletal pain
|
Musculoskeletal pain
|
10.4%
|
10.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Asthenia
|
Fatigue
|
2.29% - 13.2%
|
2.29% - 5.48%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Asthenia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Fatigue
|
Fatigue
|
2.29% - 13.2%
|
2.29% - 5.48%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Malaise
|
Malaise
|
2.29% - 13.2%
|
2.29% - 5.48%
|
|
|
x
|
x
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Discomfort
|
Malaise
|
2.29% - 13.2%
|
2.29% - 5.48%
|
|
|
x
|
x
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Feeling abnormal
|
Malaise
|
2.29% - 13.2%
|
2.29% - 5.48%
|
|
|
x
|
x
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Ill-defined disorder
|
Malaise
|
2.29% - 13.2%
|
2.29% - 5.48%
|
|
|
x
|
x
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Hypoxia
|
Hypoxia
|
8.91%
|
6.59%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Body temperature increased
|
Body temperature increased
|
1.83% - 8.18%
|
1.1% - 6.4%
|
x
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
x
|
|
x
|
Genital disorder female
|
Genital disorder female
|
6.55%
|
6.21%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
Constipation
|
Constipation
|
common, 0.382% - 9.09%
|
0.382%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anxiety
|
Anxiety
|
2.01% - 6.49%
|
2.93% - 6.43%
|
|
|
x
|
x
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Agitation
|
Agitation
|
2.01% - 6.49%
|
2.93% - 6.43%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Bradycardia
|
Bradycardia
|
postmarketing — 5.82%
|
5.65%
|
|
x
|
|
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dizziness
|
Dizziness
|
postmarketing — 0.01% - 12.2%
|
4.58% - 16.1%
|
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Syncope
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Chills
|
Shivering
|
5.09% - 6.95%
|
5.65% - 7.13%
|
|
|
x
|
x
|
|
|
x
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Urinary retention
|
Urinary retention
|
3.11% - 5.09%
|
2.74% - 3.39%
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Dry mouth
|
Dry mouth
|
common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Anorectal discomfort
|
Burning rectal
|
common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Feeling hot
|
Sensation of warmth
|
common
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Warmth
|
1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Hypotension
|
Hypotension
|
postmarketing — 1.83% - 4.91%
|
2.19% - 6.03%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Pruritus
|
Pruritus
|
1.65% - 4.91%
|
0.548% - 3.77%
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
|
|
x
|
|
x
|
|
x
|
Diarrhoea
|
Diarrhoea
|
1.79% - 44%
|
0.898% - 18%
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Injection site reaction
|
Injection site reaction
|
common, 3.84%
|
3.29%
|
|
x
|
|
|
x
|
|
|
|
|
x
|
x
|
x
|
|
|
|
x
|
|
x
|
|
x
|
Chest pain
|
Chest pain
|
postmarketing — 2.19%
|
2.74%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dysuria
|
Dysuria
|
2.01%
|
1.65%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Paraesthesia
|
Paraesthesia
|
1.65%
|
0.366%
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Feeling cold
|
Feeling cold
|
1.65%
|
1.46%
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Procedural pain
|
Post procedural pain
|
1.19%
|
1.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Dyskinesia
|
Dyskinesia
|
uncommon
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
x
|
|
Movement disorder
|
uncommon
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
x
|
|
Orofacial dyskinesia
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Movement disorder
|
Movement disorder
|
uncommon
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
x
|
|
Convulsion
|
Convulsion
|
uncommon
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Liver function test abnormal
|
Raised liver function tests
|
postmarketing, uncommon
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Anaphylactic shock
|
Anaphylactic shock
|
postmarketing, rare
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anaphylactoid reaction
|
|
|
|
|
x
|
x
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
x
|
Angina pectoris
|
Angina pectoris
|
postmarketing
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Angioedema
|
Angioedema
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Arrhythmia
|
Arrhythmia
|
postmarketing, uncommon
|
|
|
x
|
|
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Atrial fibrillation
|
Atrial fibrillation
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Bronchospasm
|
Bronchospasm
|
postmarketing, 0.595%
|
1.8%
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Neoplasm malignant
|
Neoplasm malignant
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
x
|
|
|
|
|
Cardiovascular disorder
|
Cardiovascular disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Dyspnoea
|
Dyspnoea
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Toxic epidermal necrolysis
|
Toxic epidermal necrolysis
|
very rare, postmarketing
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
x
|
|
Eye disorder
|
Eye disorder
|
postmarketing
|
|
|
x
|
|
x
|
x
|
x
|
|
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Flushing
|
Flushing
|
postmarketing, common
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hiccups
|
Hiccups
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hypersensitivity
|
Hypersensitivity
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Type I hypersensitivity
|
Type I hypersensitivity
|
rare
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Laryngeal oedema
|
Laryngeal oedema
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Laryngospasm
|
Laryngospasm
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Mediastinal disorder
|
Mediastinal disorder
|
postmarketing
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Myocardial infarction
|
Myocardial infarction
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Acute coronary syndrome
|
Myocardial infarction
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Nervous system disorder
|
Nervous system disorder
|
postmarketing
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Pain
|
Pain
|
postmarketing, 2.19%
|
2.93%
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Palpitations
|
Palpitations
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Shock
|
Shock
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Syncope
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Erythema multiforme
|
Stevens-Johnson syndrome
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
x
|
|
Stevens-Johnson syndrome
|
Stevens-Johnson syndrome
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
x
|
|
Stridor
|
Stridor
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Syncope
|
Syncope
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Loss of consciousness
|
Syncope
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Supraventricular tachycardia
|
Supraventricular tachycardia
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Torsade de pointes
|
Torsade de pointes
|
rare
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Tremor
|
Tremor
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Urticaria
|
Urticaria
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Angiopathy
|
Angiopathy
|
rare
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Vomiting
|
Vomiting
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hepatic failure
|
Hepatic failure
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Oculogyric crisis
|
Oculogyric crisis
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Ventricular extrasystoles
|
Ventricular extrasystoles
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Myocardial ischaemia
|
Myocardial ischaemia
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Opisthotonus
|
Opisthotonus
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Accommodation disorder
|
Accommodation disorder
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Blindness transient
|
Blindness transient
|
very rare, postmarketing
|
|
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Atrioventricular block second degree
|
Atrioventricular block second degree
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Hepatobiliary disease
|
Hepatobiliary disease
|
postmarketing
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Erythema
|
Redness
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
|
x
|
x
|
Vision blurred
|
Vision blurred
|
postmarketing
|
|
|
x
|
|
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Blindness
|
Blindness
|
postmarketing
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Electrocardiogram ST segment depression
|
Electrocardiogram ST segment depression
|
postmarketing, uncommon
|
|
|
x
|
|
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Procedural nausea
|
Nausea postoperative
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Injection site pain
|
Injection site burning
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Dystonia
|
Dystonic reaction
|
postmarketing — 0% - 5%
|
0%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Visual impairment
|
Visual disturbance
|
rare
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
x
|
x
|
|
|
x
|
x
|
x
|
|
Cardio-respiratory arrest
|
Cardio-respiratory arrest
|
postmarketing
|
|
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
Local reaction
|
Local reaction
|
postmarketing
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
x
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Electrocardiogram QT prolonged
|
Electrocardiogram QT corrected interval prolonged
|
rare
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Lymphocyte transformation test positive
|
Lymphocyte transformation test positive
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
|
Toxic skin eruption
|
Toxic skin eruption
|
very rare
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Abdominal pain
|
Abdominal pain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Gastrointestinal pain
|
Abdominal pain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
x
|
x
|
|
Asthma
|
Asthma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Cough
|
Cough
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Ear disorder
|
Ear disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Dermatitis
|
Rash
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Rash
|
Rash
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Flatulence
|
Flatulence
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Gastrointestinal disorder
|
Gastrointestinal disorder
|
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Cardiac disorder
|
Cardiac disorder
|
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Haemorrhage
|
Haemorrhage
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Haemoglobin
|
Haemorrhage
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Hypokalaemia
|
Hypokalaemia
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Immune system disorder
|
Immune system disorder
|
|
|
|
x
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Liver disorder
|
Liver disorder
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Hepatocellular injury
|
Liver disorder
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Foetor hepaticus
|
Liver disorder
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Sleep disorder
|
Sleep disturbance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Swelling
|
Swelling
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Tachycardia
|
Tachycardia
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Urinary tract infection
|
Urinary tract infection
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Aspartate aminotransferase increased
|
Aspartate aminotransferase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
|
x
|
|
x
|
|
Skin disorder
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anaphylactoid reaction
|
Anaphylactoid reaction
|
|
|
|
|
x
|
x
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
x
|
Akathisia
|
Akathisia
|
0% - 6%
|
0%
|
x
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
Grand mal convulsion
|
Tonic-clonic seizures
|
|
|
x
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
x
|
|
|
|
x
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 14 |
Source: | FDA Structured Product Label |
---|
Side effects: | 31 |
Source: | Medsafe |
---|
Side effects: | 34 |
Source: | FDA Structured Product Label |
---|
Side effects: | 35 |
Source: | FDA Structured Product Label |
---|
Side effects: | 36 |
Source: | Medsafe |
---|
Side effects: | 39 |
Source: | FDA Structured Product Label |
---|
Side effects: | 42 |
Source: | FDA |
---|
Side effects: | 43 |
Source: | FDA Structured Product Label |
---|
Side effects: | 48 |
Source: | FDA Structured Product Label |
---|
Side effects: | 49 |
Source: | FDA Structured Product Label |
---|
Side effects: | 51 |
Source: | FDA Structured Product Label |
---|
Side effects: | 52 |
Source: | FDA Structured Product Label |
---|
Side effects: | 53 |
Source: | Health Canada |
---|
Side effects: | 54 |
Source: | Health Canada |
---|
Side effects: | 55 |
Source: | Health Canada |
---|
Side effects: | 55 |
Source: | FDA Structured Product Label |
---|
Side effects: | 57 |
Source: | Health Canada |
---|
Side effects: | 59 |
Source: | medicines.org.au |
---|
Side effects: | 61 |
Source: | Health Canada |
---|
Side effects: | 61 |
Source: | FDA Structured Product Label |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|